Linda Zane, Ph.D.
Dr. Linda Zane has expertise in human T-cell leukemia virus type 1 (HTLV1), epigenetics, and next generation sequencing (NGS)-based diagnostic tests, as well as experience in clinical trial development. She manages a portfolio of grants focusing on genomic variation, omics technologies, and nuclear architecture.
She is excited about the advancement of technology and computational tools used in cancer biology. According to her, “It really helps with understanding the importance of 3D genome organization and the impact that nuclear processes can have in cancer.”
Research Programs
Dr. Zane is also involved in an NIH Common Fund Program:
Background
Prior to coming to DCB, Dr. Zane was a program director in the NCI Division of Cancer Treatment and Diagnosis (DCTD). She was a part of the Cancer Diagnosis Program in the Diagnostic Biomarkers and Technology Branch, which stimulates and supports research to develop new biomarkers, diagnostic strategies, modeling, innovative technologies and improved devices that will lead to better tools for research and that can assist clinical decision-making.
Dr. Zane came to DCB because of the division’s passion for basic science and the opportunity to support emerging areas of cancer research.
Education
- Ph.D., Oncovirology, University Claude Bernard Lyon 1
- M.S., Biotechnology Engineering, ENSTBB, University Bordeaux II
- B.S., Biochemistry, Pierre and Marie Curie Paris VI University